Compare GSK plc (GSK) vs The Coca-Cola Co K (KO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs The Coca-Cola Co K — how do they compare? GSK plc trades at $46.82 (market cap $91.88B), while The Coca-Cola Co K trades at $87.34 (market cap $377.63B). The key difference: The Coca-Cola Co K is far larger — about 4.1× GSK plc's market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and The Coca-Cola Co K for 154 Days on average.
| GSK | KO | |
|---|---|---|
Market Cap | $91.88B | $377.63B |
Volume | 7,730,529 | 14,894,568 |
Sector | Health | Consumer Staples |
52-Week High | $61.18 | $91.99 |
52-Week Low | $43.24 | $66.37 |
Typical Hold Time | 93 Days | 154 Days |
Enterprise Value | $111.88B | $404.81B |
Dividend Yield | 3.9% | 2.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $47.02, up 0.9% today, with a bearish technical signal but strong fundamentals. The company reported revenue of $32.67B in 2025 with a net income margin of 14.52% and has beaten EPS estimates for three consecutive quarters. Recent news highlights strategic oncology investments and a $750M deal for a cancer therapy, signaling growth initiatives.
The outlook is mixed: solid profitability and a reasonable P/E of 15.1 support value, but technical indicators show bearish pressure near key support at $46. Risks include patent expirations and competitive pressures, while analyst sentiment is cautious with 31% buy ratings. Upside depends on pipeline execution and cost savings.
Coca-Cola (KO) trades at $85.82, down 0.41% on the day, with technical indicators showing bearish momentum despite strong fundamentals. The company reported consistent earnings beats in recent quarters with Q2 2026 EPS of $0.97 beating expectations of $0.92. Revenue growth remains steady at $47.94B for 2025, with net income margin improving to 28.56%. Analyst consensus remains bullish with a $95.75 price target, representing 11.6% upside potential from current levels.
The stock presents a compelling dividend opportunity with 64 consecutive years of dividend increases, though technical weakness and regional demand divergence pose near-term risks. Long-term investors may find value in the company's stable cash flows and global brand strength, while short-term traders should monitor support at $85 for potential entry points.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About The Coca-Cola Co K
The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →
